Ipratropium nebules under Tier 3 shortage, supply gaps projected into 2026

Health Canada declared a Tier 3 shortage of ipratropium bromide nebules, with both Teva (Sterinebs) and Pharmascience (PMS-Ipratropium) affected by manufacturing disruptions; intermittent shortages and supply gaps are projected to last into 2026. Pharmacists dispensing for COPD/asthma nebulizer patients should expect ongoing constraints and substitute to ipratropium HFA pressurized metered-dose inhalers (with spacer) where clinically appropriate.

ScopeUp summarizes Ontario practice updates and links every item to its official source. Verify details against the source document before changing workflows.